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Background: Chronic obstructive pulmonary disease (COPD) affects millions worldwide. Although many therapies
exist and are being developed to relieve symptoms and reduce mortality, few data are available to understand
which of the therapeutic alternatives is the most cost-effective for COPD patients in everyday clinical practice,
especially for traditional Chinese medicine (TCM). Comparative effectiveness research can help patients, clinicians,
and decision-makers make best informed treatment decisions where such evidence was previously lacking. This
study aims to compare the effectiveness and economic evaluation of three treatments: (1) conventional Western
medicine; (2) TCM treatments, which have been evaluated and have certain effect; and (3) a combination of both
conventional Western medicine and TCM treatments, and then determine which treatment is the most suitable for
COPD patients.
Methods/design: A multicenter, pragmatic, randomized, controlled trial is adopted. A total of 360 patients will be
recruited and randomly assigned to one of the three treatments group, with 120 in each group. Patients in the
conventional Western medicine group will be given Salbutamol, Formoterol, Salmeterol/fluticasone, respectively,
according to the guidelines. For the TCM group, patients will be given Bufei granule, Bu-Fei Jian-Pi granule, Bu-Fei
Yi-Shen granule, and Yi-Qi Zi-Shen granule based on their corresponding TCM syndrome patterns, respectively. For
the combination of conventional medicine and TCM treatments group, patients will be given a combination of
conventional Western medicine and TCM granules. Treatments in each group are recognized as a whole
comprehensive intervention. After the 26-week treatment, another 26 weeks will be followed up. The outcome
measures including the frequency and duration of acute exacerbations, lung function, dyspnea, exercise capacity,
quality of life, and economic evaluation will be assessed.
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Discussion: It is hypothesized that each of the three treatments will have beneficial effects in reducing the
frequency and duration of acute exacerbations, improving exercise capacity and psychosocial function of COPD
patients. In addition, the combination of conventional medicine and TCM treatments may be most suitable for
COPD patients with better effectiveness and economic evaluation.
Trial registration: ClinicalTrials.gov NCT01836016.
Keywords: Chronic obstructive pulmonary disease, Comparative effectiveness research, Traditional Chinese
medicineBackground
Chronic obstructive pulmonary disease (COPD) is a
common, preventable, and treatable disease character-
ized by progressive airflow limitation. COPD affects
millions worldwide and remains a leading cause of
morbidity, mortality, and elevated healthcare costs
worldwide [1]. The projection for 2030 indicates that
COPD will be the third leading cause of death world-
wide [2]. In China, the overall prevalence is 8.2% in
individuals aged 40 years or older, and an estimated 65
million people will die of COPD between 2003 and
2033 [3]. In the United States, the total economic cost
of COPD was $49.9 billion in 2010, which included
approximately $29.5 billion in direct expenditures per
year [4]. Hence, strategies and management for both pri-
mary and secondary prevention and treatment should be
well developed.
Although many therapies exist and are being developed
to relieve symptoms and reduce the mortality, most were
demonstrated in placebo-controlled efficacy studies with
highly selected patient populations in tightly controlled
study settings [5,6]. Few data are available to compare the
therapeutic alternatives by randomized clinical trials in
everyday clinical practice. Much of the comparative re-
search evidence for COPD was obtained by observational
studies [7]. Furthermore, studies in real world populations
of COPD who received different therapies that do have ef-
ficacy evidence were found wide variations in care delivery
[8]. The above considerations highlight the need to iden-
tify the most cost-effective therapies and translate them
into healthcare for millions of COPD patients [9]. In short,
there is a need for comparative effectiveness research
(CER) in COPD.
CER has received growing attention worldwide [10],
which is defined as ‘the conduct and synthesis of research
comparing the benefits and harms of different interven-
tions and strategies to prevent, diagnose, treat, and moni-
tor health conditions in “real world” settings’ [11]. The
direct comparisons of treatments provided by CER can
help patients, clinicians, and decision-makers make best
informed treatment decisions where such evidence waspreviously lacking [12], especially for traditional Chinese
medicine (TCM).
The remarkable longevity and current popularity of
TCM for COPD implies its potential advantages. Our
previous randomized controlled trials on comprehen-
sive TCM interventions, especially based on the TCM
patterns, have certain evidence indicating definite effect
for COPD patients [13,14]. When facing many treatment
approaches, it is difficult to identify the most suitable
treatment. Therefore, this study aims to compare the ef-
fectiveness and economic evaluation of three treatments:
(1) conventional Western medicine; (2) TCM treatments,
which have been evaluated and have certain effect; and
(3) a combination of both conventional Western medi-
cine and TCM treatments, and then determine which
treatment is the most suitable for COPD patients.
Methods/design
Study design
This is a multicenter, pragmatic, randomized, controlled
trial to evaluate the effectiveness and economic evaluation
of three treatments in COPD patients. A total of 360 pa-
tients will be recruited and randomly assigned to one of
the three treatments group. After the 26-week treatment
period, another 26 weeks will be followed up. The out-
come measures including the frequency of exacerbations,
lung function, dyspnea, exercise capacity, quality of life,
and economic evaluation will be assessed.
Participants
Inclusion criteria
To participate in the study, COPD patients should meet
the following criteria: (1) the diagnostic criteria of COPD
[15,16]; (2) the TCM syndrome pattern criteria [14,17]
(pattern of lung qi deficiency, pattern of lung-spleen qi
deficiency, pattern of lung-kidney qi deficiency, pattern
of lung-kidney qi and yin deficiency); (3) medically stable
and confirmed diagnosis of mild to very severe COPD;
(4) aged between 18 and 80 years; (5) without participa-
tions in other interventional trials in the previous 1 month;
(6) with informed signed consent.
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Patients will be excluded for the following reasons:
(1) pregnant or breast-feeding women; (2) any psychiatric
condition rendering the patient unable to understand
the nature, scope, and possible consequences of the study;
(3) malignancy for which patient has undergone resection,
radiation therapy, or chemotherapy within the last 5 years;
(4) current respiratory disorders other than COPD (for ex-
ample, bronchiectasis, tuberculosis, lung fibrosis, pulmon-
ary thromboembolic); (5) complicated with heart failure
(Grade III or IV New York Heart Association Functional
Classification) or myocardial infarction within 6 months
or unstable hemodynamics; (6) complicated with serious
hepatic and renal diseases (liver cirrhosis, portal hyper-
tension, bleeding of varicose veins, dialysis, or renal
transplantation); (7) participating in other trials or
allergic to the used medicine.
Ethics and recruitment
All patients will sign the informed consent before inclu-
sion. The study has been approved by the Ethical Research
Committees of the First Affiliated Hospital of Henan
University of Traditional Chinese Medicine with identi-
fier 2013HL004-01. Any revisions of the study protocol
will be submitted to the ethics committee.
COPD patients will be recruited from either the out-
patient department or open recruitment and be ob-
served in six research centers, which are the First
Affiliated Hospital of Henan University of Traditional
Chinese Medicine, Shuguang Hospital Affiliated to
Shanghai University of Traditional Chinese Medicine,
The Second Affiliated Hospital of Liaoning University
of Traditional Chinese Medicine, Shanxi Provincial
Traditional Chinese Medicine, The Affiliated Hospital
of Jiangxi University of Traditional Chinese Medicine,
and Henan University Huaihe Hospital. Recruitment
will last for a period of 6 months from November 2013
or until a sample of 360 patients are enrolled.
Sample size
The frequency of acute exacerbation of COPD is con-










) was based on a com-
parison among the equal numbers of a multiple samples
mean. From a previous study [13,14], the number of the
exacerbation frequency was 1.17 times every year by
treatment of conventional medicine, and that was 0.97
times every year by treatment of TCM, and that was
0.68 times every year by treatment of both conventional
medicine and TCM. The two-sided alpha level was 0.05,
and the beta level was 0.01, the ψ value was 2.52, the k
value was 3. Using the calculation, the sample size ineach group was approximately 100. Allowing for a 20%
dropout rate over the course of the study, the sample
size would be approximately 120.Therefore, the total
sample size was 360, with 120 in each group.
Randomization
Treatment allocation will occur when the participants
meet the inclusion criteria and sign the informed con-
sent form. A stratified and block randomization design
is adopted. The number of the groups is three and the
distribution ratio is 1-to-1. Considering the long time
for treatment observation, the process is divided into
more than one block, and the length of the block is six.
The number of center hierarchical levels was six. A ran-
dom number from 001 to 360 is generated by SAS 9.2
and saved in a sealed envelope by an independent clinical
statistician. In the event of a clinical emergency, the indi-
vidual’s randomization code and group allocation could be
identified by the emergency envelope as soon as possible.
The randomization design is provided by the DME de-
partment of Nanjing University of Traditional Chinese
Medicine.
Interventions
Patients in the conventional medicine group will be divided
into Groups A, B, C, or D, and then given Salbutamol, For-
moterol, Salmeterol/fluticasone for 26 weeks, respectively,
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) and Chinese Treatment Guidelines.
The choice within each group of medication commonly
used in treating COPD depends on the patient-specific
combined COPD assessment as the relationship between
severity of symptoms, risk of exacerbations, drug availabil-
ity, and the patient’s response. The pharmacologic therapy
(three drugs) for COPD patients is recognized as a whole
comprehensive intervention rather than one drug for each
group. The whole comprehensive Western intervention is
shown in Table 1.
For the TCM treatments group, patients will be given
herbal interventions based on the TCM syndrome pat-
terns, respectively, which are Bufei granule for lung qi
deficiency, Bu-Fei Jian-Pi granule for lung-spleen qi de-
ficiency, Bu-Fei Yi-Shen granule for lung-kidney qi defi-
ciency, and Yi-Qi Zi-Shen granule for lung-kidney qi
and yin deficiency. The herbal interventions are also
recognized as a whole comprehensive intervention. The
TCM granules are compound preparations of Chinese
herbs and its main components are shown in Table 2.
Each type of granule comes in packs of four bags. Each
bag of Bu-Fei granule (batch number: 1305402) contains
6.35 g, and that of Bu-Fei Jian-Pi granule (batch num-
ber: 1305403) is 5.82 g, Bu-Fei Yi-Shen granule (batch
number: 1305404) is 5.33 g, Yi-Qi Zi-Shen granule
(batch number: 1305405) is 5.37 g. These components
Table 1 Comprehensive Western intervention for stable
COPD patients
Classification Therapy
Group A Salbutamol (Ventolin®, GlaxoSmithKline) 100 μg/dose,
200 inhalations. Dosing: one inhalation of 100 μg each
time (when needed), and the maximum dose is 8 to 12
inhalations a day
Group B Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5 μg/dose,
60 inhalations. Dosing: one inhalation of 4.5 μg each
time, twice daily
Group C Salmeterol/fluticasone (Seretide®, GlaxoSmithKline),
50/500 μg/dose, 60 inhalations. Dosing: one inhalation
of 50/500 μg each time, twice daily
Group D Salmeterol/fluticasone (Seretide®, GlaxoSmithKline),
50/500 μg/dose, 60 inhalations. Dosing: one inhalation
of 50/500 μg each time, twice daily
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Yin Tian Jiang Pharmaceutical Co. Ltd. with the authenti-
cation quality of Goods Manufacturing Practice (Approval
Number: SU J0677), Jiangsu, PR China. The test results of
drug quality were consistent with the required quality
standards. Each type of granule will be given orally, two
bags each time, twice a day for 26 weeks.
For the combination of conventional medicine and TCM
treatments group, patients will be given the combinationTable 2 Main components of traditional Chinese
medicine treatment
Chinese name Latin name Amount (g)
Bu-Fei granule for pattern of lung qi deficiency
Dang Shen Codonopsis pilosula 15
Ai Di Cha Herba ardisiae Japonicae 15
Zi Wan Radix asteris 9
Chen Pi Pericarpium citri reticulatae 9
Bu-Fei Jian-Pi granule for pattern of lung-spleen qi deficiency
Huang Qi Astragalus propinquus 15
Dang Shen Codonopsis pilosula 15
Bai Zhu Atractylodes macrocephala 12
Fu Ling Wolfiporia extensa 12
Bu-Fei Yi-Shen granule for pattern of lung-kidney qi deficiency
Ren Shen Radix Ginseng 9
Huang Qi Astragalus propinquus 15
Gou Qi Zi Lycium barbarum 12
Shan Zhu Yu Cornus officinalis 12
Yin Yang Huo Epimedium brevicornu 9
Yi-Qi Zi-Shen granule for pattern of lung-kidney qi and yin
deficiency
Ren Shen Radix Ginseng 9
Huang Jing Polygonatum sibiricum 15
Shu Di Huang Rehmannia glutinosa 15
Mai Dong Ophiopogon japonicus 15
Wu Wei Zi Schisandra chinensis 9of conventional Western medicine and TCM granules as
stated above for 26 weeks.
Outcome measure
Primary outcome measure
Exacerbations of COPD The frequency and duration of
acute exacerbations of COPD (AECOPD) is the primary
outcome measure. AECOPD is characterized by a change
in patients’ original conditions of dyspnea, cough, and (or)
expectoration in the development of the disease, which is
beyond daily routine variation, and requires a change in
regular medication [18]. Its reductions are a major goal of
COPD management and an important indicator for evalu-
ating the treatments. The frequency of AECOPD is the
interval between two acute exacerbations in more than
1 week. If the interval between two onsets of acute exacer-
bation is within 1 week, it is counted as one number acute
exacerbation. The duration of AECOPD is measured from
the beginning of the acute exacerbation to the symptoms
the patient feels reduce significantly or restore to the level
before acute exacerbation. The number of frequency and
duration of AECOPD occurred each time during the 26-
week treatment period and 26-week follow-up, and then
count the total number and average number of frequency
and duration.
The secondary outcome measures
Lung function The indicators of forced vital capacity
(FVC), forced expiratory volume in 1 s (FEV1) and FEV1
percentage of the predicted value (FEV1%) will be tested.
A positive change from baseline in them will indicate
the improvement in lung function.
Dyspnea The Modified Medical Research Council (MMRC)
by the American Thoracic Society [19] will be assessed
to evaluate the level of dyspnea. The MMRC scale is a
simple grading system that scored from 0 (less severe)
to 4 (severe).
The 6-minute walking distance (6MWD) This is to
evaluate the distance a person can walk on a flat surface
in 6 min to assess the exercise capacity.
Quality of life The COPD Assessment Test (CAT) will
be adopted. The CAT is the self-complete questionnaires
with eight items, each formatted as a semantic six-point
ranging from 0 to 5. Range of CAT scores from 0 to 40.
Higher scores denote a more severe impact of patient’s
quality of life [20]. The patients will be invited to complete
the questionnaires through face-to-face survey. The pa-
tients can answer each question and check the most ap-
propriate opinion (a specific score) in their standards,
hopes, pleasures, and concerns. Meanwhile, an investiga-
tor in each center will be assigned in the office to help the
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naire to ensure that the patients answer all the questions.
Economic evaluation The Cost-Effective Analysis (CEA)
and Cost Utility Analysis (CUA) will be assessed through
calculation the incremental cost-effectiveness ratio and in-
cremental mean cost per quality-adjusted life year [21]. A
specific questionnaire is designed to collect self-reported
cost-related data by patients. The total costs include direct
costs and indirect costs. The direct costs comprise medical
costs and non-medical costs. Besides the costs of four
herbal formulas and three drugs, the direct medical costs
include diagnostic and lab investigations, oxygen therapy,
and the average costs of acute exacerbations managed in
the outpatient and inpatient settings. The non-medical
costs include traveling expenses, accommodation, cater-
ing, and transportation costs to the clinic. The indirect
costs were calculated using the human capital method,
which consists of duration of sick leaves, lost productivity,
travel and waiting time, and nursing.
Safety The routine blood, urine, and stool tests, liver
and kidney function tests, and an electrocardiogram are
performed. Adverse events will be recorded at any time
during the treatment period and follow-up period.
The MMRC, 6MWD, CAT will be recorded at baseline
(week 0), in the third month (week 13) and sixth month
(week 26) during the treatment period, and at the third
month (week 39) and sixth month (week 52) during the
follow-up period. The lung function will be observed at
weeks 0, 26, and 52. Safety will be measured at weeks 0
and 26. The date of economic evaluation will be measured
at week 52.
Quality control
To ensure the quality of this study, the framework of ap-
propriate planning before the trial, adequate oversight
and monitoring, and verification will be executed. The
standard operating procedures (SOPs) for trial execution
will be implemented to ensure the accuracy and integrity
of clinical data at each step of the trial, such as identifica-
tion, registration, and recruitment. Periodic monitoring
will be applied by telephone and email. The completion
and compliance of paper case report forms (CRFs), the
clinical trial procedures, such as compliance with adminis-
tration and the withdrawal of participants in each center
will also be audited.
Statistical analysis
The intention-to-treat analysis (ITT) and per-protocol
analysis (PP) will be adopted. An ITT analysis will be used
to analyze the baseline data and clinical evaluation data of
the randomized patients in the groups to which they will
be randomly assigned, regardless of their adherence withthe treatment, and regardless of subsequent withdrawal
from treatment or deviation from the protocol. Partially
missing data of the clinical evaluation will be carried for-
ward with the principle of the last visit carried forward
(LOCF). PP analysis set will be used to analyze the clinical
evaluation data of the patients who are considered to be
adherent to the protocol with better compliance. All
statistical analyses will be undertaken using SAS9.2
(KEY: FQ37-WSB8-7G5C).
All P values will be two-tailed and the α level of signifi-
cance will be set at 0.05. Measurement data will be pre-
sented as mean ± SD, median, inter-quartile range. The
one way analysis of variance (ANOVA) will be used firstly
to compare the statistical significance among the three
groups followed by a post-hoc test such as Tukey’s for
multiple comparisons when the data are normally distrib-
uted, or a Kruskal Wallis test followed by Mann-Whitney
U-tests with a Bonferonni correction will be used if the
data are not normally distributed. Since treatment and
time course will be investigated, as well as center effect
interaction, the analysis of covariance (ANCOVA) will be
adopted by using proc GLM for each outcome variable.
The repeated measures ANOVA will be used compare the
value differences of more than two measures are taken in
different time point for the same participants, such as the
symptoms, MMRC, 6MWD, CAT before treatment, the
third month and sixth month in the treatment period, and
the third and sixth months during the follow-up period.
The paired-sampled t test or signed rank sum test will be
used to compare the value differences between pre-
treatment and post-treatment within one group. The Chi
square test will be used to compare the value differences
in safety among the three groups. The cost-effectiveness
analysis and cost-utility analysis will be adopted for health
economic evaluation. The whole procedure of this study is
shown in Figure 1.
Discussion
Through comparing the applicability and/or superiority of
a particular therapy among the existing options in practice
or development, CER can narrow the translation gap
between clinical research and everyday clinical practice
as well as to deliver more cost effective healthcare [22].
It is generally agreed that a wide range of research
methods, such as pragmatic clinical trials, prospective
observational studies, prospective or retrospective regis-
tries, meta-analyses, and technology assessments can be
applied in CER [23]. The pragmatic randomized con-
trolled trial (PRCT), with broader inclusion criteria that
are more reflective of the general patient population
and less strict follow-up monitoring, can achieve a balance
between internal validity and relevance, while maintaining
the fundamental features of high-quality clinical trials
[24,25]. Therefore, the PRCT is adopted by this study to
Figure 1 Technical route of this comparative effectiveness research study.
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the experiences of patients in real-world settings and cir-
cumstances. To our knowledge, this study will be the first
CER in conventional medicine, TCM treatments and a
combination of both conventional medicine and TCM
treatments in China specifically designed to determine
which treatment is the most suitable for COPD patients.
Currently, more and more alternative approaches have
been used in COPD patients [26]. Through a series of
hard work, the TCM granules, Bu-Fei granule, Bu-Fei
Jian-Pi granule, Bu-Fei Yi-Shen granule, and Yi-Qi Zi-
Shen granule, have definite effect evidence [13,14,27].
First, based on our long experience in clinical practice,
combined with expert counseling many times, the initial
framework of the four granules is formed. Meanwhile,
through the experimental studies, the mechanism of
them is explored and further optimization is performed
on its formulas. In addition, the lager sample random-
ized controlled trials are conducted to evaluate its effi-
cacy. Finally, the four granules are made and used in this
study according to strict quality standards.
Due to the nature of pragmatic randomized controlled
trial and CER design, the double blinded design is not
adopted in our study. Although the study is an open-
label trial, however, some measures will be considered to
strengthen quality control. To avoid the bias from the
researchers’ in the procedure of this study, an investiga-
tor separate from all of the clinical researchers will be
assigned in each research center as the contact person
who preserve and record the randomization information.Therefore, the clinical researchers do not have any effect
on enrollment or randomization. Meanwhile outcome
assessments will be made by an independent clinical
statistician blinded to group allocation and uninvolved in
providing intervention or management. However, there
are some limitations of the study. On the one hand, the 6-
month treatment period and 6-month follow-up duration
is a little short to observe the changes in lung function
and then show the full effect of three treatments. On
the other hand, other therapies for COPD, such as pul-
monary rehabilitation, are not set separately. Further stud-
ies should be performed to evaluate all COPD treatments.
Trial status
At the time of manuscript submission, we had recruited
60 patients but not completed the patient recruitment.
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